الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
The global obesity epidemic is expected to greatly increase the prevalence of metabolic syndrome (MetS) and diabetes mellitus (DM) by the year 2030. Obesity, dyslipidemia, insulin resistance, hypertension, and hyperglycemia are the multiplex of clinical traits that define MetS.
Because of its far-reaching effects on global health, MetS research is urgently needed to identify new risk factors for its development and progression.
Recently, the interaction between ANGPTL8 (betatrophin) and ANGPTL3 has been shown to play a role in regulating lipid metabolism. One ANGPTL8 sequence variant has been linked to HDL and LDL cholesterol levels that are lower than average.
The rs2278426 (C > T) polymorphism at c194 is very common in ANGPTL8 studies and has been shown to affect the activated form of ANGPTL3 and can be exposed to LPL inhibition, which is related to low plasma levels of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C).
This genetic association hasn’t been previously tested in the Egyptian population. For this reason, the current work was conducted study the association of ANGPTL8 gene variant (Rs2278426 (C/T)) with metabolic syndrome in a cohort of Egyptian patients.